The NICE agenda

The agenda of drug products being scrutinized by the National Institute for Clinical Excellence (NICE) over the next year, accompanied by its comments identifying the issues under review, and listing companies marketing in the product category (see Online Links, A6).




NICE comments

Bristol-Myers Squibb


Rhône-Poulenc Rorer

Paclitaxel (Taxol)

Docetaxel (Taxotere)

Ovarian cancer,

breast cancer

Breast cancer

There is uncertainty among British medics over the use of currently used in advanced breast cancer with possible new indications in the future. NICE will provide definitive advice on the available evidence.

AstraZeneca plc

TAP Holdings Inc.

Proton pump inhibitors (PPIs)

Treatment of dyspepsia

PPIs are extremely clinically and cost effective for some patients, but there is evidence of their inappropriate use in treatment of minor diseases which would have responded to other treatments, and failure to attack the underlying cause of ulcers by using H-pylori eradication therapy after initial treatment of symptoms with a PPI. Clear guidance from NICE offers the potential for both significantly enhanced quality of care with potential savings.